Spots Global Cancer Trial Database for waldenstrom's macroglobulinemia
Every month we try and update this database with for waldenstrom's macroglobulinemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | NCT00422656 | Waldenstrom's M... | Perifosine | 18 Years - | Dana-Farber Cancer Institute | |
| Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | NCT00265928 | Lymphoma | bortezomib rituximab antibody therap... biological ther... enzyme inhibito... monoclonal anti... | 18 Years - | National Cancer Institute (NCI) | |
| Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies | NCT00150462 | Waldenstrom's M... Non-Hodgkin's L... Hodgkin's Disea... Multiple Myelom... | Carfilzomib Dexamethasone | 18 Years - | Amgen | |
| Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia | NCT02400437 | Waldenstrom's M... | Ixazomib Dexamethasone Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing | NCT02604511 | Waldenstrom's M... | Ibrutinib | 18 Years - | Dana-Farber Cancer Institute | |
| Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's | NCT02371148 | Waldenstrom's M... | Bortezomib-Ritu... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders | NCT01177527 | Multiple Myelom... Waldenstrom's M... Smoldering Mult... Lymphoblastic L... | 18 Years - | Dana-Farber Cancer Institute | ||
| Trial of AVN-944 in Patients With Advanced Hematologic Malignancies | NCT00273936 | Acute Leukemia Chronic Leukemi... Multiple Myelom... Hodgkin's Lymph... Non-Hodgkin's L... Waldenstrom's M... | AVN-944 capsule... | 18 Years - | Vertex Pharmaceuticals Incorporated | |
| Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood | NCT00146055 | Myeloma, Plasma... Lymphoma, Malig... Myeloproliferat... Myelodysplastic... Waldenstrom's M... | Reduced intensi... | - | University of Michigan Rogel Cancer Center | |
| Study of VTD in Waldenstrom's Macroglobulinemia | NCT03335098 | Waldenstrom Mac... Lymphoplasmacyt... | Bortezomib | 19 Years - | Seoul National University Hospital | |
| Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) | NCT00422799 | Waldenstrom's M... | Bortezomib Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia | NCT00142129 | Waldenstrom's M... Lymphoplasmacyt... | Bortezomib (Vel... | 18 Years - 90 Years | Dana-Farber Cancer Institute | |
| A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 | NCT04274738 | Waldenstrom's M... | Mavorixafor Ibrutinib | 18 Years - | X4 Pharmaceuticals | |
| S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. | NCT00919139 | Multiple Myelom... Smoldering Myel... Waldenstrom's M... Monoclonal Gamm... Amyloidosis | biologic sample... | - | SWOG Cancer Research Network | |
| Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | NCT01647971 | Non-Hodgkins Ly... B-cell Lymphoma Waldenstrom's M... Marginal Zone L... Chronic Lymphoc... Small Lymphocyt... Primary Central... | Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia | NCT00142129 | Waldenstrom's M... Lymphoplasmacyt... | Bortezomib (Vel... | 18 Years - 90 Years | Dana-Farber Cancer Institute | |
| Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | NCT02142530 | Non-Hodgkin Lym... Diffuse Large B... Mantle Cell Lym... Follicular Lymp... Peripheral T-ce... | Carfilzomib Belinostat | 18 Years - | Massachusetts General Hospital | |
| Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy | NCT02381080 | B-Cell Chronic ... | Ibrutinib Erythromycin Voriconazole | 18 Years - | Janssen Research & Development, LLC | |
| Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | NCT01125293 | Waldenstrom's M... | Everolimus Rituximab Bortezomib | 18 Years - | Dana-Farber Cancer Institute | |
| Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors | NCT02071888 | Non-Hodgkin's L... Multiple Myelom... Waldenstrom's M... Other B-cell NH... T-cell NHL | CB-839 CB-839 and low ... CB-839, pomalid... | 18 Years - | Calithera Biosciences, Inc | |
| Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia | NCT01046006 | Waldenstrom's M... | Bortezomib, Rit... | 18 Years - | University of Athens | |
| Study of MLN8237 in Participants With Advanced Hematological Malignancies | NCT00697346 | B-cell Follicul... B-cell Marginal... Diffuse Large B... B-cell Mantle C... B-cell Small Ly... B-Cell Chronic ... Multiple Myelom... Waldenstrom's M... Noncutaneous Pe... Angioimmunoblas... Anaplastic Larg... Enteropathy Ass... NK Lymphoma | Alisertib | 18 Years - | Takeda | |
| Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia | NCT01614821 | Waldenstrom's M... | PCI-32765 | 18 Years - | Dana-Farber Cancer Institute | |
| LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia | NCT00936611 | Waldenstrom's M... | LBH589 | 18 Years - | Dana-Farber Cancer Institute | |
| Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood | NCT00146055 | Myeloma, Plasma... Lymphoma, Malig... Myeloproliferat... Myelodysplastic... Waldenstrom's M... | Reduced intensi... | - | University of Michigan Rogel Cancer Center | |
| A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 | NCT04274738 | Waldenstrom's M... | Mavorixafor Ibrutinib | 18 Years - | X4 Pharmaceuticals | |
| Study of MLN8237 in Participants With Advanced Hematological Malignancies | NCT00697346 | B-cell Follicul... B-cell Marginal... Diffuse Large B... B-cell Mantle C... B-cell Small Ly... B-Cell Chronic ... Multiple Myelom... Waldenstrom's M... Noncutaneous Pe... Angioimmunoblas... Anaplastic Larg... Enteropathy Ass... NK Lymphoma | Alisertib | 18 Years - | Takeda | |
| Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood | NCT00146055 | Myeloma, Plasma... Lymphoma, Malig... Myeloproliferat... Myelodysplastic... Waldenstrom's M... | Reduced intensi... | - | University of Michigan Rogel Cancer Center | |
| LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia | NCT00936611 | Waldenstrom's M... | LBH589 | 18 Years - | Dana-Farber Cancer Institute | |
| Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | NCT02142530 | Non-Hodgkin Lym... Diffuse Large B... Mantle Cell Lym... Follicular Lymp... Peripheral T-ce... | Carfilzomib Belinostat | 18 Years - | Massachusetts General Hospital | |
| Simvastatin in Waldenstrom's Macroglobulinemia | NCT00575965 | Waldenstrom's M... | Simvastatin | 18 Years - | Dana-Farber Cancer Institute | |
| Study of MLN8237 in Participants With Advanced Hematological Malignancies | NCT00697346 | B-cell Follicul... B-cell Marginal... Diffuse Large B... B-cell Mantle C... B-cell Small Ly... B-Cell Chronic ... Multiple Myelom... Waldenstrom's M... Noncutaneous Pe... Angioimmunoblas... Anaplastic Larg... Enteropathy Ass... NK Lymphoma | Alisertib | 18 Years - | Takeda | |
| Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia | NCT00250926 | Waldenstrom's M... | Bortezomib Dexamethasone Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia | NCT00113802 | Waldenstrom Mac... | Epratuzumab (hL... | 18 Years - | Gilead Sciences | |
| Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia | NCT01470196 | Waldenstrom's M... | Dexamethasone Carfilzomib Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. | NCT00919139 | Multiple Myelom... Smoldering Myel... Waldenstrom's M... Monoclonal Gamm... Amyloidosis | biologic sample... | - | SWOG Cancer Research Network | |
| Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia | NCT00142129 | Waldenstrom's M... Lymphoplasmacyt... | Bortezomib (Vel... | 18 Years - 90 Years | Dana-Farber Cancer Institute | |
| Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia | NCT02439138 | Waldenstrom's M... | GS-1101 | 18 Years - | Dana-Farber Cancer Institute | |
| Trial of AVN-944 in Patients With Advanced Hematologic Malignancies | NCT00273936 | Acute Leukemia Chronic Leukemi... Multiple Myelom... Hodgkin's Lymph... Non-Hodgkin's L... Waldenstrom's M... | AVN-944 capsule... | 18 Years - | Vertex Pharmaceuticals Incorporated | |
| Study of VTD in Waldenstrom's Macroglobulinemia | NCT03335098 | Waldenstrom Mac... Lymphoplasmacyt... | Bortezomib | 19 Years - | Seoul National University Hospital | |
| Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia | NCT01046006 | Waldenstrom's M... | Bortezomib, Rit... | 18 Years - | University of Athens | |
| Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood | NCT00146055 | Myeloma, Plasma... Lymphoma, Malig... Myeloproliferat... Myelodysplastic... Waldenstrom's M... | Reduced intensi... | - | University of Michigan Rogel Cancer Center | |
| Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia | NCT02092909 | Waldenstrom's M... | IMO-8400 | 18 Years - | Idera Pharmaceuticals, Inc. | |
| Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders | NCT01177527 | Multiple Myelom... Waldenstrom's M... Smoldering Mult... Lymphoblastic L... | 18 Years - | Dana-Farber Cancer Institute | ||
| A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies | NCT00807677 | Acute Myeloid L... Acute Lymphobla... Chronic Myeloge... Chronic Lymphoc... Multiple Myelom... Waldenstrom's M... Myelodysplastic... Philadelphia Ch... Myeloid Metapla... Myelofibrosis Advanced Polycy... Non-Hodgkins Ly... | TAK-901 | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 | NCT04274738 | Waldenstrom's M... | Mavorixafor Ibrutinib | 18 Years - | X4 Pharmaceuticals | |
| Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy | NCT02381080 | B-Cell Chronic ... | Ibrutinib Erythromycin Voriconazole | 18 Years - | Janssen Research & Development, LLC | |
| A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma | NCT00081809 | Lymphoma, Folli... Lymphoma, Small... | autologous huma... | - | Agenus Inc. | |
| Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab | NCT00667329 | Lymphoma | 2CdA Cyclophosphamid... Rituximab | - | M.D. Anderson Cancer Center | |
| Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab | NCT00667329 | Lymphoma | 2CdA Cyclophosphamid... Rituximab | - | M.D. Anderson Cancer Center | |
| Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | NCT01125293 | Waldenstrom's M... | Everolimus Rituximab Bortezomib | 18 Years - | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
